Cure8 research brief
Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.
Pediatric patients with IBD on infliximab, their parents/caregivers, gastroenterology clinicians who manage biologic therapy, and teams interested in medication access/insurance policy.
This prospective cohort enrolled patients <18 years in maintenance remission on IFX-IV who transitioned to IFX-SC. About 61% of those prescribed started SC therapy; insurance denials were a common barrier.
At the primary timepoint (≥12 weeks) and at a median ~7 months follow-up, 91% (20/22) remained in clinical remission by disease activity scores without corticosteroids, hospitalization, surgery, or stopping therapy. Measured infliximab concentrations roughly doubled after switching (median increase from IV trough to SC steady-state).
Two participants who previously had anti-drug antibodies had clearance after the switch. Adverse events were mostly mild (injection-site pain, transient pruritus, device misfire); no serious adverse events or anaphylaxis were reported.
Reported findings come from a prospective single-center cohort with limited sample size and follow-up; results are promising but not from a randomized trial. The summary is grounded in the article abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
